Pivotal Two-Year Results on Xience V Drug-Eluting Stent Published

Data published online in Circulation from the SPIRIT III U.S. pivotal trial evaluating the XIENCE V Everolimus Eluting Coronary Stent System demonstrated that Abbott’s market-leading XIENCE V outperforms the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in reducing major adverse cardiac events (MACE) at two years.
CNN Money